The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.
November 29th 2023
A trial randomizing brain-dead donor hearts to levothyroxine administration or saline has returned results challenging conventional wisdom on the topic, with data indicating thyroid hormone administration may provide no significant benefit.
November 16th 2023
Ankeet Bhatt, MD, MBA provides additional perspective on a recent study examining the cost-effectiveness and health impact of sacubitril/valsartan use at different thresholds of ejection fraction.
Data from a phase 1b trial presented at HFSA 2023 detail the effects of JK07, an investigational agent from Salubris Biotherapeutics, in patients with heart failure with reduced ejection fraction.
A study presented at HFSA 2023 offers clinicians an overview of the influence of socioeconomic status on access to implantable hemodynamic monitors using the National Inpatient Sample.
Announced on October 9, the decision to issue a CRL is based on the FDA's belief the clinical meaningfulness of patisiran’s treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established.
Hosts are joined by Marat Fudim, MD, MHS, of Duke, to discuss the REBALANCE-HF trial, which examined endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction.
The REBALANCE-HF trial at HFSA 2023 reveals that right greater splanchnic nerve ablation was well-tolerated and safe in patients with HFpEF, with additional analysis shedding light on the proportion of responders to the procedure.
Anand Shah, MD, MBA, provides insights into a study he led examining the impact of out-of-pocket costs and insurance type on uptake of GDMT in patients with heart failure with reduced ejection fraction.
A propensity score-matched analysis of data suggests use of spironolactone could reduce the 3-year risk of developing Alzheimer disease or dementia among patients with heart failure with reduced ejection fraction.
José López, MD, discusses the results of a study he led examining contemporary trends in racial disparities as it pertains to LVAD utilization in patients with heart failure with reduced ejection fraction.
Muthiah Vaduganathan, MD, MPH, offers insight and perspective into a new annual report from the Heart Failure Society of America outlining trends in epidemiology and outcomes in heart failure.
Data from the EMPEROR-Reduced trial provide insight into the effects of empagliflozin in patients with heart failure with reduced ejection fraction based on baseline diuretic use from the phase 3 trial.
Results of the 56-week VALOR-HCM trial provide new insight into the effects of mavacamten in patients with highly symptomatic obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.
Less than 2 weeks after the release of their SELECT reaction podcast, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down for a special edition episode of Diabetes Dialogue to discuss STEP-HFpEF data and the implications for semaglutide 2.4 mg.